Fresh analysis suggests that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt conventional lifestyle plans.
Published data in a leading health publication shows that while overweight individuals frequently drop substantial amounts of their body weight while on the medication, the mass returns at an average rate of 0.8 kg per month once they quit.
"Users buying such medications must be informed of the danger of rapid rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
This pace of regain implies a reversion to pre-treatment mass in about a year and a half.
Comparing Therapies
The analysis, which examined dozens of studies involving over 9,000 of participants, compared the outcomes of these new drugs with conventional dieting.
Scientists note that people who shed pounds through lifestyle changes alone usually have a less rapid creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Doctors propose the mechanism of the jabs accounts for the heightened weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement leads to appetite is uncontrolled, making binge eating far more likely."
A Lifelong Condition?
Health authorities suggest the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, considering the high risk of weight regain, the therapy is often ongoing.
This opinion is reinforced by pharmaceutical companies, who note that the results "emphasize the long-term nature of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the jabs describe a intense resurgence of cravings.
"It was like something activating and you're instantly extremely hungry," said an individual.
The struggle is compounded if users have not established sustainable dietary or behavioural modifications during therapy.
Significant Adoption
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is more common among females than men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, experts caution that while these medications are potent agents for weight loss, they are not a permanent solution and maintained weight loss relies on combined behavioural support.
